<- Go Home
Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is based in Palo Alto, California. Eidos Therapeutics, Inc. operates as a subsidiary of BridgeBio Pharma, Inc.
Market Cap
$4.8B
Volume
120.1K
Cash and Equivalents
$147.3M
EBITDA
-$97.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$127.0K
Profit Margin
100.00%
52 Week High
$132.54
52 Week Low
$28.39
Dividend
N/A
Price / Book Value
38.39
Price / Earnings
-46.09
Price / Tangible Book Value
38.39
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$97.9M
Return on Equity
70.31%
Return on Assets
-35.95
Cash and Short Term Investments
$147.3M
Debt
$21.5M
Equity
$122.9M
Revenue
$127.0K
Unlevered FCF
-$48.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium